Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)

Figure 2

Rate of in-hospital complications (panel A) and 30-day major cardiovascular events (panel B) by treatment group (Number of events appear at the base of each specific column). For panel A, composite endpoint (compared to other oral) were: 0.129 (95% CI 0.036–0.465) for the DPP4i group and 0.388 (95% CI 0.225–0.667) for the Metformin group. For panel B, composite endpoint (compared to other oral) were: 0.157 (95% CI 0.05–0.50) for the DPP4i group and 0.491 (95% CI 0.288–0.837) for the Metformin group. “*” indicates a p value of less than 0.05.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840